Antidepressant effectiveness in severe depression and melancholia

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 4, 1999, Pages 14-22

  Schatzberg, Alan F ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ASCENDIN; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MAPROTILINE; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE;

CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GERIATRIC CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MELANCHOLIA; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; HUMANS; MORPHOLINES; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0033001851     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-52
2. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138
3. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
4. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-1739
5. Schatzberg AF. Treatment of severe depression with the selective serotonin reuptake inhibitors. Depression Anxiety 1996;4:182-189
6. Zimmerman M, Spitzer RL, Melancholia: from DSM-III to DSM-III-R. Am J Psychiatry 1989;146:20-28
7. Nierenberg AA. The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 1994;55(9, suppl A):55-61
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
9. Rush AJ, Weissenburger JE. Melancholic symptom features and DSM-IV. Am J Psychiatry 1994;151:489-498
10. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry 1991;148:1512-1517
11. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 1991;48:796-800
12. Pande A, Sayler M. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993;8:243-245
13. Nelson JC, Mazure CM, Jatlow PI. Desipramine treatment of major depression in patients over 75 years of age. J Clin Psychopharmacol 1995;15: 99-105
14. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-291
15. Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:305-322
16. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992;7:91-94
17. Stuppaeck CH, Geretsegger C, Whitworth AB, et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994;14:241-246
18. Wheadon D. Presented at the 32nd Annual Meeting of the American College of Neuropsychopharmacology; December 1993; Honolulu, Hawaii
19. Ottevanger EA. The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:731-740
20. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990;51(12, suppl B):28-33
21. Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993;13: 305-310
22. Schatzberg AF, Rosenbaum AH, Orsulak PJ, et al. Toward a biochemical classification of depressive disorders, III: pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline. Psychopharmacology (Berl) 1981;75:34-38
23. Rosenbaum AH, Schatzberg AF, Maruta T, et al. MHPG as a predictor of antidepressant response to imipramine and maprotiline. Am J Psychiatry 1980;137:1090-1092
24. Clerc GE, Ruimy P, Verdeau-Pailles J, on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143
25. Rudolph RL, Derivan AT, for the Venlafaxine XR 211 Study Group. Double-blind, placebo-controlled study of once-daily venlafaxine XR and fluoxetine in depressed outpatients. In: Scientific Abstracts of the 36th Annual Meeting of the American College of Neuropsychiatry; December 8-12, 1997; Waikoloa, Hawaii
26. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
27. Nierenberg AA, Feighner J, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
28. Cole J, Schatzberg A, Sniffin C, et al. Trazodone in treatment of resistant depression: an open study. J Clin Psychopharmacol 1981;1(6, suppl): 49S-54S
29. Silverstone PH, Ravindran AV, Hamel R. Once-daily venlafaxine XR versus fluoxetine in outpatients with depression and concomitant anxiety. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association; June 2, 1998; Toronto, Ontario, Canada. Abstract NR392:173
30. Rizzo F, Smeraldi E. Double-blind, randomized trial of venlafaxine, clomipramine and trazodone in elderly depressed patients. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association; June 4, 1998: Toronto, Ontario, Canada. Abstract NR647:242
31. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59(suppl 14):8-10
32. Rothschild AJ, Samson JA, Bessette MP, et al. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993;54:338-342
33. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-436
34. Gatti F, Bellini L, Gasperini M, et al. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996;153:414-416
35. Zanardi R, Franchini L, Gasperini M, et al. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996;153:1631-1633